Literature DB >> 32462756

How should colorectal surgeons practice during the COVID-19 epidemic? A retrospective single-centre analysis based on real-world data from China.

Changzheng He1, Yuxuan Li1, Xiaohui Huang1, Shidong Hu1, Yang Yan1, Yichen Liu1, Pengyue Zhao1, Haiguan Lin1, Xiaolei Xu1, Yufeng Wang2, Da Teng1, Xiaohui Du1.   

Abstract

BACKGROUND: The coronavirus disease 2019 is currently of global concern. Cancer patients are advised to stay at home in case of potential infection, which may cause delays of routine diagnosis and necessary treatment. How colorectal surgeons should manage this during the epidemic remains a big challenge. The objective of the study is to evaluate the feasibility of routine colorectal surgery during coronavirus disease 2019 and to offer some Chinese recommendations to colorectal surgeons throughout the world.
METHODS: A total of 166 patients receiving colorectal surgery from 20 December 2019 to 20 March 2020 at Department of General Surgery in Chinese General Hospital of People's Liberation Army were enrolled, and further divided into two groups based on before or after admission date of 20 January 2020. Clinicopathologic data such as hospital stay and economic data such as total costs were collected and analysed retrospectively.
RESULTS: Longer hospital stay, higher proportion of non-local patients and more hospitalization cost were found in the post-20 January group (special-time group) (P < 0.001; P < 0.05; P < 0.05, respectively). Apart from this, no difference existed with regard to baseline demographical data such as age, sex and height, as well as clinicopathological data such as previous history, surgery time, operation extent and TNM staging.
CONCLUSIONS: This real-world study indicated that performing colorectal surgery during coronavirus disease 2019 epidemic might be safe and feasible based on comprehensive screening and investigation. We have summarized several recommendations here, hoping to help surgeons from related departments across the world.
© 2020 Royal Australasian College of Surgeons.

Entities:  

Keywords:  colorectal surgery; coronavirus disease 2019; realworld data; retrospective analysis

Mesh:

Year:  2020        PMID: 32462756      PMCID: PMC7283805          DOI: 10.1111/ans.16057

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   2.025


Introduction

Currently, the whole world is facing a big challenge of the novel virus pneumonia known as coronavirus disease 2019 (COVID‐19) named officially by World Health Organization. Since it broke out in Wuhan, Hubei Province of China in late December 2019 initially as reported, the COVID‐19 has caused hundreds of thousands of people to be infected and resulted in a heavy burden on the global economy. As a result of the rising numbers, verified person‐to‐person transmission and different health security capacities between countries, , , the World Health Organization has already declared COVID‐19 a Public Health Emergency of International Concern. A nationwide analysis about cancer and COVID‐19 in China revealed that patients infected with this virus were more likely to have a history of cancer and cancer patients had higher risks of COVID‐19 and poorer outcomes from it. Some researchers summarized that for cancer patients who were advised to stay at home during the global COVID‐19 pandemic, potential risks existed for lacking early diagnosis, delaying of clinical therapy and further causing potential disease progression and poor prognosis. Thus, we should pay more attention to those patients with cancer, especially the elderly as some reports have shown that older patients tend to have lower immune functions and worse COVID‐19 outcomes. , Researchers from Italy proposed that the COVID‐19 epidemic could postpone outpatient visits, early test screening, oncological follow‐up and endoscopy examination for patients with colorectal cancer (CRC). Delay of treatment for cancer was associated with decreasing survival years and increasing medical costs. , Therefore, it is vital to ensure colorectal surgery is performed safely and effectively during this special time. To date, we have carried out several measures and put forward a Chinese expert consensus on surgical diagnosis and treatment strategies for CRC patients during COVID‐19 epidemic. In this retrospective study, we enrolled all those CRC patients receiving surgical treatment in our hospital around this COVID‐19 outbreak period, collected and analysed aspects such as safety and costs to conduct surgery for CRC. Meanwhile, we have introduced several precautions based on real‐world data and hope to exchange our learning experiences with intestinal surgeons around the world.

Methods

In Beijing, China, the first confirmed case of COVID‐19 was officially announced by Beijing government on 20 January 2020, and the number of new cases reached zero on 20 March 2020. Thus, it was considered that the time of the epidemic situation was from 20 January 2020 to 20 March 2020, and we chose period from 20 December 2019 to 20 January 2020 as a control normal time in our study. CRC patients hospitalized at General Surgery Department of Chinese General Hospital of People's Liberation Army (Beijing, China) from 20 December 2019 to 20 March 2020 were enrolled, and the inclusion criteria were as follows: (i) all patients received surgical treatment, including radical surgery for CRC and other non‐radical surgery; (ii) operations were all performed by experienced senior surgeons; (iii) CRC patients were diagnosis based on pathological examination and all clinical data were integral and available. Patients who underwent emergency surgery were excluded. All patients signed informed consent before surgery and this study was approved by ethics committee of Chinese General Hospital of People's Liberation Army. Since 20 January 2020, we have applied intensified strategies in case of COVID‐19 infection, composed of three aspects of outpatient, inpatient, and discharged patient management. After 20 March 2020, the epidemic situation of COVID‐19 began to stabilize, and hospital admissions gradually recovered. All the enrolled patients were divided into normal‐time group (NTG) and special‐time group (STG) based on hospitalization date. Clinical data were collected from those patients meeting inclusive and exclusive criteria above. Measurement data with normal distribution were presented as mean ± standard deviation and analysed via t test. Enumeration data were displayed as n (%) and analysed using chi‐squared test. P < 0.05 was considered statistically significant, and all the statistical analyses were accomplished with IBM SPSS 23.0 (IBM, Armonk, NY, USA).

Results

Study population and baseline demographics

A total of 166 patients were enrolled, with 95 patients into NTG who were hospitalized before 20 January 2020 and the remaining 71 patients in the STG. Patients demographics for NTG and STG are shown in Table 1. The differences between NTG and STG were similar with regard to age, sex, height and weight (P > 0.05). The origin of patients between two groups showed a significant difference, with proportion of non‐local patients of NTG significantly higher than that of STG (P < 0.05).
Table 1

Baseline demographical data of all patients enrolled

DemographicsNTG (n = 95)STG (n = 71) P
Age (years), mean ± SD60.34 ± 11.3059.77 ± 12.350.757
Sex, n 0.216
Male7046
Female2525
Height (cm), mean ± SD167.96 ± 7.35167.54 ± 8.700.735
Weight (kg), mean ± SD70.62 ± 12.9169.75 ± 12.790.664
Origin of patients, n 0.035*
Local1117
Nonlocal8454

P < 0.05, statistically different.

NTG, normal time group; SD, standard deviation; STG, special time group.

Baseline demographical data of all patients enrolled P < 0.05, statistically different. NTG, normal time group; SD, standard deviation; STG, special time group.

Clinicopathological data of all patients enrolled before or after 20th January

Preoperatively, patients had similar characteristics with respect to waiting time for hospitalization, imaging examinations of computed tomography, magnetic resonance imaging or positron emission tomography computed tomography and colonoscopy, previous disease, major admission diagnosis and history of neoadjuvant chemotherapy (NACT) (P > 0.05). Compared to STG, patients in NTG had longer length of hospital stay before surgery (P < 0.05) (Table 2).
Table 2

Preoperative clinicopathological data of all patients enrolled

Clinicopathologic dataNTG (n = 95)STG (n = 71) P
Admission waiting (day), mean ± SD7.95 ± 13.979.59 ± 14.190.470
Previous history, n 0.801
Yes5341
No4230
Major diagnosis, n 0.590
Duodenal cancer11
Colon cancer4333
Rectal cancer4228
Interstitialoma31
Benign diseases66
Other02
CT examination, n 0.158
Plain913
Enhanced7453
None125
MRI examination, n 0.374
Plain21
Enhanced1912
None7458
PET/CT examination, n 0.467
Yes1412
No8159
Enteroscope test, n 0.051
Yes8960
No510
History of NACT, n 0.739
Yes21
No9370
Hospital stay before surgery (day), mean ± SD4.68 ± 5.887.42 ± 3.620.001*

P < 0.05, statistically different.

CT, computed tomography; MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy; NTG, normal time group; PET/CT, positron emission tomography computed tomography; SD, standard deviation; STG, special time group.

Preoperative clinicopathological data of all patients enrolled P < 0.05, statistically different. CT, computed tomography; MRI, magnetic resonance imaging; NACT, neoadjuvant chemotherapy; NTG, normal time group; PET/CT, positron emission tomography computed tomography; SD, standard deviation; STG, special time group. Intraoperatively, no statistically significant differences existed in terms of surgery time, operative method, resection extent, dissection of lymph nodes, combined organ resection or transfusion of blood (P > 0.05) (Table 3).
Table 3

Intraoperative clinicopathological data of all patients enrolled

Clinicopathologic dataNTG (n = 95)STG (n = 71) P
Surgery time (min), mean ± SD157.79 ± 60.51167.45 ± 83.580.389
Operative method, n 0.472
Open2010
Laparoscopic7059
Conversion to open42
Other10
Resection extent, n 0.083
Local/non‐radical144
Radical8064
Extended radical13
Dissection of LNs, n 0.822
D27656
D377
Unclear44
None84
Combine organ resection, n 0.420
Yes46
No9165
Transfusion of blood, n 0.393
Yes68
No8963

*P < 0.05, statistically different.

LNs, lymph nodes; NTG, normal time group; SD, standard deviation; STG, special time group.

Intraoperative clinicopathological data of all patients enrolled *P < 0.05, statistically different. LNs, lymph nodes; NTG, normal time group; SD, standard deviation; STG, special time group. Postoperatively, there were no statistically significant differences for pathological diagnosis, TNM staging, complication including pneumonia and blood transfusion, as well as highest temperature, screening test, and reason for fever between the two groups (P > 0.05). Compared to NTG, patients of STG had more fever after surgery, longer length of postoperative stay and total stay (P < 0.05) (Table 4).
Table 4

Postoperative clinicopathological data of all patients enrolled

Clinicopathologic dataNTG (n = 95)STG (n = 71) P
Pathological diagnosis, n 0.370
Primary disease9362
Metastatic disease23
TNM staging, n 0.241
Stage I139
Stage II2228
Stage III4124
Stage IV115
Benign disease85
Complication, n 0.996
Yes43
No9168
Fever (≥37.3°C), n 0.006*
Yes2735
No6836
Highest temperature (°C), n 0.119
<37.36836
37.3–38.52125
>38.5610
Screening examination, n 0.192
BRE1012
BRE + CRP1717
BRE + CRP + X‐ray + CT01
~ + Fistulography01
None6840
Reason of fever, n 0.106
Abdominal infection73
Pulmonary infection01
Incision infection10
Anastomotic leakage02
Other1824
Unclear11
None6840
Transfusion of blood, n 0.253
Yes36
No9265
Hospital stay after surgery (day), mean ± SD7.02 ± 3.809.00 ± 3.780.001*
Total hospital stays (day), mean ± SD11.78 ± 7.4316.70 ± 5.800.000*

P < 0.05, statistically different.

BRE, blood routine examination; CRP, C‐reactive protein; CT, computed tomography; NTG, normal time group; SD, standard deviation; STG, special time group.

Postoperative clinicopathological data of all patients enrolled P < 0.05, statistically different. BRE, blood routine examination; CRP, C‐reactive protein; CT, computed tomography; NTG, normal time group; SD, standard deviation; STG, special time group.

Health economics data of all patients enrolled before or after 20th January

We analysed health economics data especially and results showed that patients of STG had higher costs of laboratory tests, anaesthesia, total hospitalization expenses and other costs (P < 0.05). Other costs include beds, carers, diets and heating bills. Costs were similar concerning medicine, examination, treatment, surgery and medical consumables (P > 0.05). The results were shown in Table 5.
Table 5

Health economics data of all patients enrolled

Health economics data (10 000 RMB)NTG (n = 95), mean ± SDSTG (n = 71), mean ± SD P
Medicine2.40 ± 1.002.66 ± 1.180.126
Laboratory test1.04 ± 0.331.17 ± 0.400.022*
Examination0.10 ± 0.230.11 ± 0.170.847
Treatment0.60 ± 1.020.69 ± 1.100.581
Surgery0.44 ± 0.110.47 ± 0.120.054
Anaesthesia0.19 ± 0.060.21 ± 0.070.037*
Consumables2.90 ± 0.893.15 ± 0.950.082
Others0.32 ± 0.460.45 ± 0.180.021*
Total costs7.99 ± 2.518.91 ± 2.470.020*

P < 0.05, statistically different.

NTG, normal time group; RMB, Renminbi; SD, standard deviation; STG, special time group.

Health economics data of all patients enrolled P < 0.05, statistically different. NTG, normal time group; RMB, Renminbi; SD, standard deviation; STG, special time group.

Discussion

According to the latest figures by the Center for Systems Science and Engineering at Johns Hopkins University, there are more than 5 920 000 confirmed cases of COVID‐19 throughout the world and over 360 000 deaths from it. Currently, the USA with more than 1 740 000 confirmed cases and over 100 000 deaths, has already surpassed China and ranks first place among all the countries. CRC, one of the most common malignant tumours, has over 1.8 million new cases and more than 900 000 fatal cases every year, ranking third and second place globally for morbidity and mortality, respectively, and in addition, there is also a younger and increasing trend of CRC in China, which has raised concern both in China and across the world. , The outbreak of COVID‐19 resulted in potential risks for cancer patients that delays of diagnosis and treatment might cause disease progression and survival shortening. How to run a colorectal surgery department effectively in this special time remains a big challenge. In this study, during COVID‐19 epidemic, non‐local patients visiting our hospital decreased owing to strategies of traffic restriction and reducing movement of people. As Table 2 shows, preoperative examinations including computed tomography, magnetic resonance imaging and positron emission tomography computed tomography were similar, with ongoing screening of patients with suspected symptoms, signs, temperature and epidemiological (COVID exposure) history. Information about operations revealed that conducting surgery during COVID‐19 is feasible. However, lengths of preoperative, postoperative and total hospital stay were all significantly longer and cost of hospitalization and treatment were notably higher, which was related to a three‐day observation and isolation before operation. Fever after surgery occurred more often in STG patients, most of which were associated with stress response postoperatively, after comprehensive testing and investigation. And after further grouping and analysing, postoperative fever conditions showed no statistically differences as shown in Table 4. On behalf of Group of Colorectal Surgery, Society of Surgery, Chinese Medical association, our team drafted and published a Chinese expert consensus on surgical diagnosis and treatment strategies for CRC patients during COVID‐19 epidemic. We recommended several strategies, in order to not only accomplish the prevention and control of COVID‐19 but also promote diagnosis and treatment for CRC safely and orderly, including three aspects of outpatient, inpatient and postoperative patient management. Flowchart of diagnosis and treatment for CRC patients during COVID‐19 is shown in Figure 1.
Fig 1

Flowchart of diagnosis and treatment for colorectal cancer patients during COVID‐19. CC, colon cancer; CRC, colorectal cancer; MDT, multiple disciplinary treatment; NAT, neoadjuvant therapy; RC, rectal cancer; WWS, watch and wait strategy.

Flowchart of diagnosis and treatment for colorectal cancer patients during COVID‐19. CC, colon cancer; CRC, colorectal cancer; MDT, multiple disciplinary treatment; NAT, neoadjuvant therapy; RC, rectal cancer; WWS, watch and wait strategy. Firstly, several tips for outpatient management should be addressed: (i) medical staff in outpatient must wear medical surgical mask or N95 mask, as well as disposable helmet, gloves and goggles, to protect them from potential infection; (ii) appointment and triage protocols should be carried out through telephone, smartphone apps or internet service and patients visit the clinic based on reservation number and recommended time, to reduce crowds gathering and lower risks of cross infection; (iii) for primary‐care patients, triage nurses need to measure their temperature and investigate epidemiological history including travelling to Wuhan in Hubei Province and nearby cities, meeting with people who have been in those areas, and contact with confirmed or suspected cases within 14 days, as well as clinical manifestations including fever (>37.3°C), fatigue and respiratory symptoms like coughing. For those with history of exposure or symptoms, the fever clinic screening had to be done first. Multidisciplinary team (MDT) meetings with doctors from General Surgery, Medical Oncology, Radiology, Radiotherapy, Respiratory and Epidemiology carried out via internet is recommended, for the sake of working out a personalized plan of diagnosis and treatment. Secondly, perioperative management varies depending on type of surgical procedure. All hospitalized patients have to be isolated separately for at least 3 days, and only after all‐round investigations of clinical symptoms and signs, laboratory test and imaging examinations, should operations be arranged. According to the latest version of the Standard of Diagnosis and Treatment of Colorectal Cancer in China, most CRC patients are diagnosed with advanced tumour. For cT4 colon cancer, cT3‐4/N+ rectal cancer or CRC patients with resectable metastatic disease, NACT is recommended. FOLFOX and CapeOX both work for those CRC patients when given as NACT or adjuvant chemotherapy. , , We propose CapeOX as first choice during COVID‐19 epidemic, on account of its convenient method of taking oral medications for most of the time. Although neoadjuvant radiotherapy (NART) is proposed for rectal cancer patients, some research has showed that outcomes seemed not compromised without routine NART. Thus, to some extent, NART could be postponed until COVID‐19 epidemic ended. For CRC patients with unresectable metastasis, NACT plus bevacizumab or cetuximab is proposed. Selective operation strategy is proposed for those CRC patients with locally advanced or metastatic disease. Limited endoscopic therapy should be performed for cT1N0M0 CRC patients, whereas limited operation should be done for cT2‐3N0M0 colon cancer or cT2N0M0 rectal cancer patients. Researchers from England put forward that no association existed between delay of treatment and survival of CRC patients, yet advised that for this issue, colon and rectum should be analysed separately. Heo and colleagues found that over 30 days of treatment delays was associated with poorer survival for rectum instead of colon cancer. Moreover, waiting about 2 months after NACT and NART for rectal cancer did not increase response rate but adversely influenced morbidity from surgery. Therefore, for advanced colon cancer patients, the watch and wait strategy could be applied during COVID‐19 epidemic. For advanced rectal tumours with demands of limited surgery, as well as other conditions such as haemorrhage, perforation and obstruction in need of emergency surgery, radical operations could be performed. Thirdly, for postoperative management, the number of caregivers and visitors should be restricted and confined to fixed times for visiting. Further, mask wearing and temperature monitoring are mandatory for all personnel around the ward including medical staff, caregivers, visitors, and cleaners. For adjuvant therapy, a maximum of 60 days' delay is acceptable. After being discharged, an appropriate delay is recommended for patients who seek a review and recheck and media like telephone, WeChat or E‐mails are preferred for postoperative consultations. Experts in different areas have also summarized and shared management and working experiences , , , , , , , including departments of intensive care unit, urology, colorectal surgery, obstetrics, transplantation, oncology and dermatology. Currently, some countries have suspended all non‐urgent surgery during COVID‐19 epidemic. We believe that all should be cautious about COVID‐19, although overcorrecting for the epidemic is inappropriate. The results of our single‐centre analysis showed that it is safe to perform colorectal surgery during COVID‐19, and what needs to be done careful assessment and screening comprehensively before admission, accepting a longer length of hospital stay and an increased cost. In this study, the results were based on analysis of real‐world data from one single centre, which might lead to some bias. In addition, COVID‐19 in Beijing is not as severe as in some areas like USA, Italy, Spain, France or Wuhan in Hubei Province of China, and the public health resources, hygiene measures, populace obedience and some aspects vary in different regions, for which some of our recommendations might be impractical to imitate.

Conclusion

In conclusion, our study indicated that it might be safe and feasible to perform colorectal surgery during COVID‐19 after implementing strategies to lower risks for patients and hospital staff. We do believe this epidemic will end soon after joint efforts, and hope that some of our recommendations would be helpful for experts from other countries.

Conflicts of interest

None declared.
  32 in total

1.  Coronavirus disease 2019 and transplantation: A view from the inside.

Authors:  Andrea Gori; Daniele Dondossola; Barbara Antonelli; Davide Mangioni; Laura Alagna; Paolo Reggiani; Alessandra Bandera; Giorgio Rossi
Journal:  Am J Transplant       Date:  2020-04-12       Impact factor: 8.086

2.  Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial.

Authors:  Anders Jakobsen; Fahimeh Andersen; Anders Fischer; Lars H Jensen; Jens C R Jørgensen; Ole Larsen; Jan Lindebjerg; John Pløen; Søren R Rafaelsen; Jesper Vilandt
Journal:  Acta Oncol       Date:  2015-04-29       Impact factor: 4.089

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

4.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

5.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

6.  Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.

Authors: 
Journal:  Lancet Oncol       Date:  2012-09-25       Impact factor: 41.316

7.  Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.

Authors:  David Roder; Christos Stelios Karapetis; Ian Olver; Dorothy Keefe; Robert Padbury; James Moore; Rohit Joshi; David Wattchow; Dan L Worthley; Caroline Louise Miller; Carol Holden; Elizabeth Buckley; Kate Powell; Dianne Buranyi-Trevarton; Kellie Fusco; Timothy Price
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

8.  COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.

Authors:  Claudio Conforti; Roberta Giuffrida; Caterina Dianzani; Nicola Di Meo; Iris Zalaudek
Journal:  Dermatol Ther       Date:  2020-03-22       Impact factor: 2.851

9.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).

Authors:  Waleed Alhazzani; Morten Hylander Møller; Yaseen M Arabi; Mark Loeb; Michelle Ng Gong; Eddy Fan; Simon Oczkowski; Mitchell M Levy; Lennie Derde; Amy Dzierba; Bin Du; Michael Aboodi; Hannah Wunsch; Maurizio Cecconi; Younsuck Koh; Daniel S Chertow; Kathryn Maitland; Fayez Alshamsi; Emilie Belley-Cote; Massimiliano Greco; Matthew Laundy; Jill S Morgan; Jozef Kesecioglu; Allison McGeer; Leonard Mermel; Manoj J Mammen; Paul E Alexander; Amy Arrington; John E Centofanti; Giuseppe Citerio; Bandar Baw; Ziad A Memish; Naomi Hammond; Frederick G Hayden; Laura Evans; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2020-03-28       Impact factor: 17.440

10.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Authors:  Wenhua Liang; Weijie Guan; Ruchong Chen; Wei Wang; Jianfu Li; Ke Xu; Caichen Li; Qing Ai; Weixiang Lu; Hengrui Liang; Shiyue Li; Jianxing He
Journal:  Lancet Oncol       Date:  2020-02-14       Impact factor: 41.316

View more
  5 in total

Review 1.  The Spill-Over Impact of the Novel Coronavirus-19 Pandemic on Medical Care and Disease Outcomes in Non-communicable Diseases: A Narrative Review.

Authors:  Ivy Lynn Mak; Eric Yuk Fai Wan; Teenie Kwan Tung Wong; Wendy Woo Jung Lee; Esther Wai Yin Chan; Edmond Pui Hang Choi; Celine Sze Ling Chui; Mary Sau Man Ip; Wallace Chak Sing Lau; Kui Kai Lau; Shing Fung Lee; Ian Chi Kei Wong; Esther Yee Tak Yu; Cindy Lo Kuen Lam
Journal:  Public Health Rev       Date:  2022-04-27

2.  Acute complex appendicitis during the COVID-19 epidemic: A single-institution retrospective analysis based on real-world data.

Authors:  Yu Yang; Yuxuan Li; Xiaohui Du
Journal:  Am J Emerg Med       Date:  2021-03-11       Impact factor: 2.469

Review 3.  Impact of the COVID-19 Pandemic on Colorectal Cancer Diagnosis and Treatment: a Systematic Review.

Authors:  Afrooz Mazidimoradi; Fatemeh Hadavandsiri; Zohre Momenimovahed; Hamid Salehiniya
Journal:  J Gastrointest Cancer       Date:  2021-11-29

4.  Impact of the COVID-19 pandemic on surgical outcomes in patients undergoing colorectal cancer surgery: A retrospective study and meta-analysis of data from 11,082 participants.

Authors:  Gang Tang; Feng Pi; Jie Tao; Zhengqiang Wei
Journal:  Front Public Health       Date:  2022-09-29

5.  Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review.

Authors:  Rachel Riera; Ângela Maria Bagattini; Rafael Leite Pacheco; Daniela Vianna Pachito; Felipe Roitberg; Andre Ilbawi
Journal:  JCO Glob Oncol       Date:  2021-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.